摘要
目的:比较阿托伐他汀与瑞舒伐他汀对原发性高脂血症患者血糖水平的影响。方法:选取中国人民武装警察部队学院医院(以下简称"我院")收治的原发性高脂血症患者125例,按照入院奇偶顺序分组,奇数为阿托伐他汀组(63例),偶数为瑞舒伐他汀组(62例)。在服用他汀类药物治疗前和治疗6、12个月后,分别检测患者的血脂指标、血糖指标水平,并比较两组患者新发糖尿病发生情况和治疗成本。结果:治疗6、12个月后,两组患者的总胆固醇、三酰甘油和低密度脂蛋白胆固醇水平较治疗前明显降低,高密度脂蛋白胆固醇水平较治疗前明显升高,差异均有统计学意义(P<0.05)。治疗6个月后,两组患者空腹血糖、糖化血红蛋白水平与治疗前的差异无统计学意义,且两组间的差异也无统计学意义(P>0.05);治疗12个月后,瑞舒伐他汀组患者上述指标水平与治疗6个月时的差异无统计学意义(P>0.05),但阿托伐他汀组患者上述指标水平较治疗6个月时明显升高,且明显高于瑞舒伐他汀组,差异均有统计学意义(P<0.05)。阿托伐他汀组患者新发糖尿病发生率为7.94%(5/63),明显高于瑞舒伐他汀组的3.23%(2/62),差异有统计学意义(P<0.05);阿托伐他汀组患者的日均治疗成本、年均治疗成本均明显低于瑞舒伐他汀组,差异均有统计学意义(P<0.05)。结论:阿托伐他汀与瑞舒伐他汀对原发性高脂血症均有良好的调节血脂效果;长期口服阿托伐他汀会升高患者的血糖水平;瑞舒伐他汀虽然治疗成本较高,但其安全性比阿托伐他汀更高。
OBJECTIVE： To compare the effects between atorvastatin and rosuvastatin on blood glucose in patients with primary hyperlipidemia. METHODS： 125 patients with primary hyperlipidemia admitted into Chinese People＇s Armed Police Forces Academy Hospital were selected and numbered according to the admission sequences, patients with odd numbers were set as atorvastatin group （63 cases）, even number were rosuvastatin group （62 cases）. Levels of blood lipid and blood glucose indices were detected, incidences of new diabetes and treatment costs of two groups were compared at before treatment, 6 months and 12 months after treatment. RESULTS： At 6 months and 12 months after treatment, contents of total cholesterol （TC）, triacylglycerol （TG） and low density lipoprotein cholesterin （ LDL-C ） had been significantly reduced than those of before treatment, while the content of high density lipoprotein cholesterin （HDL-C） had been significantly increased than those of before treatment, with statistically significant differences （ P 〈 0.05）. At 6 months after treatment, there were no statistical significances in differences of fasting blood-glucose （FBG） and glycosylated hemoglobin between those of before treatment, neither between two groups （P 〉 0. 05） ; at 12 months after treatment, there were no statistical significances in differences of FBG and glycosylated hemoglobin between those of 6 months after treatment in rosuvastatin group （ P 〉 0.05 ）, while the FBG and glycosylated hemoglobin of atorvastatin group had been significantly increased and was significantly higher than those of rosuvastatin group, with statistically significant differences （ P 〈 0. 05 ）. The incidence of new diabetes of atorvastatin group was 7.94% （5/63）, which was significant higher than that of the rosuvastatin group （3.23 %, 2/62）, with statistically significant difference （P 〈 0.05 ） ; the average daily and annual treatment cost of atorvastatin zrouD were significantly lower than those of rosuvastatin group, with statistically significant difference （ P 〈 0.05 ）. CONCLUSIONS ： Both atorvastatin and rosuvastatin can regulate blood lipid in patients with primary hyperlipidemia; orally and long-term take atorvastatin will increase patients＇ blood glucose, though the treatment cost of rosuvastatin is higher, it also has higher safety than atorvastatin.
作者
赵贵石
朱芮田
黄自冲
ZHAO Guishi;ZHU Ruitian;HUANG Zichong(Dept. of Pharmacy, Chinese People＇ s Armed Police Forces Academy Hospital, Hebei Langfang 065000, China;Dept. of Internal Medicine. Chinese People＇ s Armocl P)
出处
《中国医院用药评价与分析》
2018年第4期496-498,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
